Funding for Sinai Health Netherton Syndrome project from partners Evotec and AmorChem

Funding for Sinai Health Netherton Syndrome project from partners Evotec and AmorChem

TORONTO, May 12, 2020 (GLOBE NEWSWIRE) — Toronto Innovation Acceleration Partners (TIAP), Evotec SE and AmorChem II Fund L.P. (AmorChem) are pleased to announce a $1.75M investment into a drug development project focused on a rare skin disease called Netherton Syndrome, that affects one in…

Two New Projects: Cystic Fibrosis and Respiratory Syncytial Virus

Two New Projects: Cystic Fibrosis and Respiratory Syncytial Virus

Toronto, ON, Feb. 27, 2019 (GLOBE NEWSWIRE) — MaRS Innovation announced today the concurrent launch of two new LAB150 projects. These projects build on breakthroughs in disease-focused scientific research by prominent teams at The Hospital for Sick Children (SickKids) and the University of Toronto, both…